Business Context and Reporting Period
This Form 8-K filing by Minerva Neurosciences, Inc. (NERV) reports a corporate governance event dated August 10, 2026. The filing addresses the appointment of a new Chief Accounting Officer and the reassignment of the principal accounting officer role.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Appointment: Anthony Aliquo was appointed as Chief Accounting Officer and principal accounting officer, effective August 10, 2026.
- Role Transition: Fred Ahlholm ceased serving as principal accounting officer on the same date but continues as Chief Financial Officer and principal financial officer.
- Compensation Adjustment: Mr. Aliquo's annual base salary was increased to $296,696, effective July 1, 2026. His annual performance bonus target was increased to 35% of his base salary.
Outlook, Risks, and Management Commentary
The filing contains no guidance, outlook, or discussion of risks and contingencies. Management commentary is limited to the biographical background of Mr. Aliquo, noting his CPA status, over 10 years of accounting experience, and prior roles at BDO USA, P.C. and Deloitte & Touche, LLP. The Board confirmed there are no undisclosed arrangements or family relationships influencing the appointment.
Investor Verification Checklist
- Verify the effective date of the salary increase (July 1, 2026) versus the appointment date (August 10, 2026).
- Confirm the continued tenure of Fred Ahlholm as CFO following the change in principal accounting officer.
- Review the Company's most recent 10-K or 10-Q for actual financial performance metrics, as this 8-K contains none.